Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer

Treatment options for patients with metastatic colorectal cancer (mCRC) are limited. This particularly affects the largest group of patients with RAS mutations, who are considered ineligible for therapy with antiEGFR antibodies. In this liquid biopsy-based study, we performed the first in-depth anal...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Oncol
Hlavní autoři: Klein-Scory, Susanne, Wahner, Ingo, Maslova, Marina, Al-Sewaidi, Yosef, Pohl, Michael, Mika, Thomas, Ladigan, Swetlana, Schroers, Roland, Baraniskin, Alexander
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2020
Témata:
Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7378792/
https://ncbi.nlm.nih.gov/pubmed/32766143
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.01115
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky